Wave Life Sciences
CompanyUnited States
Wave Life Sciences develops one asset, preclinical (INHBE-3 in obesity). Mostly oligonucleotide acting on lipid and ceramide metabolism, inflammation and INHBE; based in the United States.
- 1
- Asset
- Furthest stage
- Preclinical
- 0
- Trials
- 1
- Signal
Pipeline
1GalNAc-conjugated siRNA silences hepatic INHBE, lowering Activin E and modulating adipocyte lipolysis.
Preclinical, Oligonucleotide, Lipid and ceramide metabolism, Inflammation, obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Signals3
- Similar companies6
Papers
Silencing Hepatokine Activin E Promotes a Healthy Body Composition and Metabolic Profile in Mice
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
ENDO 2025 abstract, 23 Oct 2025